---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-016670"
form_type: "8-K"
ticker: "ATYR"
cik: "0001339970"
company_name: "aTYR PHARMA INC"
filed_at: "2022-08-11T23:59:59+00:00"
generated_at: "2026-06-24T00:42:21.114622+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# aTyr Pharma gets FDA Fast Track for efzofitimod in pulmonary sarcoidosis

## Summary
- FDA granted Fast Track designation on August 9, 2022 for lead candidate efzofitimod.
- Fast Track aims to expedite development and review; may allow rolling submission.
- Pulmonary sarcoidosis is a major interstitial lung disease with no approved therapies.
- Efzofitimod is a novel immunomodulator targeting neuropilin-2; Phase 3 trial ongoing.

## SEC filing metadata
- accession: 0000950170-22-016670
- form_type: 8-K
- ticker: ATYR
- cik: 0001339970
- company_name: aTYR PHARMA INC
- filed_at: 2022-08-11T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1339970/000095017022016670/0000950170-22-016670-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1339970/000095017022016670/life-20220809.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-016670
- JSON: https://secwatch.observer/filing/0000950170-22-016670.json
- Plain text: https://secwatch.observer/filing/0000950170-22-016670.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.